Loading...
•
Dec 31, 2019
Ironwood Pharmaceuticals Q4 2019 Earnings Report
Reported strong fourth quarter and full year results, exceeding full year guidance, and provided full year 2020 guidance.
Key Takeaways
Ironwood Pharmaceuticals reported strong fourth quarter and full year 2019 results, exceeding full year 2019 guidance. The company's 2019 revenue was $428 million, driven primarily by U.S. LINZESS collaboration revenue. GAAP net income from continuing operations was $59 million and adjusted EBITDA from continuing operations was $148 million for the full year 2019. 2020 total revenue and adjusted EBITDA guidance incorporates previously amended agreements with Astellas and AstraZeneca. Data readouts from MD-7246 Phase II trial and IW-3718 Phase III trials are expected in 2020.
Became a GI-focused healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of patients
Executing on strategy to drive LINZESS growth, advance late-stage GI portfolio, and deliver sustainable profits.
Made substantial progress in 2019 across each of these priorities and expect 2020 to be another pivotal year.
Settled all outstanding LINZESS patent litigation
Forward Guidance
In 2020, Ironwood expects revenue between $370 million and $390 million and adjusted EBITDA between $165 million and $185 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...